Table 3 Results table
Analysis | Denosumab | Alendronate | Differences | ICER | |||
|---|---|---|---|---|---|---|---|
Costs | QALYs | Costs | QALYs | Costs | QALYs | ||
Base case | $5483 | 5.823 | $4037 | 5.817 | $1446 | 0.006 | $246,749 |
Risk fracture equation parameters: | |||||||
Lower 95 % confidence limit ICER | $5233 | 5.829 | $3824 | 5.822 | $1346 | 0.005 | $191,164 |
Upper 95 % confidence limit ICER | $5660 | 5.840 | $4287 | 5.834 | $1431 | 0.007 | $282,342 |
% change in BMD sensitivity scenarios (see Table 1) | $5534 | 5.812 | $4123 | 5.805 | $1411 | 0.006 | $223,458 |
Year 3, 50 % of non-persistence in year 2 | $5485 | 5.825 | $4039 | 5.820 | $1445 | 0.005 | $272,323 |
Lower 95 % interval fracture SMR | $5498 | 5.860 | $4107 | 5.855 | $1391 | 0.006 | $243,293 |
Upper 95 % interval fracture SMR | $5381 | 5.769 | $3969 | 5.761 | $1412 | 0.007 | $197,015 |
Fracture costs × 0.75 | $4943 | 5.828 | $3494 | 5.822 | $1449 | 0.006 | $251,018 |
Fracture costs × 1.25 | $5924 | 5.841 | $4578 | 5.835 | $1347 | 0.006 | $217,746 |
Lower 95 % interval fracture utility multipliers | $5462 | 5.801 | $4077 | 5.792 | $1385 | 0.008 | $163,384 |
Upper 95 % interval fracture utility multipliers | $5464 | 5.866 | $4073 | 5.862 | $1392 | 0.004 | $378,871 |
‘No fracture’ utility = 1 | $5447 | 7.292 | $4056 | 7.284 | $1390 | 0.007 | $188,997 |
No discounting | $6403 | 7.117 | $4913 | 7.109 | $1490 | 0.008 | $181,755 |
All patients contribute $6.10 per prescription | $5326 | 5.839 | $3829 | 5.833 | $1497 | 0.006 | $260,582 |
Denosumab cost reduced by 50 % | $4370 | 5.835 | $4060 | 5.829 | $310 | 0.006 | $50,068 |